Hoth Therapeutics Inks Research Pact For Critical Studies Of HT-006 Antibiotic

Hoth Therapeutics Inc (NASDAQ: HOTH) has entered into a Research Agreement with the University of Cincinnati Research Institute to perform critical antimicrobial characterization studies with HT-006 as part of the streamlined drug development plan.

• HT-006 is under development as a potential treatment for multi-drug resistant bacterial lung infections, such as hospital-acquired pneumonia, cystic fibrosis, chronic obstructive pulmonary disease, and ventilator-associated pneumonia.

• Hoth previously licensed the HT-006 technology for commercial evaluation from the Walter Reed Army Institute of Research.

• The research plan includes critical antimicrobial in vitro characterization studies for HT-006 in alignment with the FDA's program for "antibacterial therapies.

• The company says that this streamlined program allows for nonclinical animal studies to reduce clinical studies required for approval.

• Price Action: HOTH gained 3.3% at $2.19 in market trading hours on the last check Wednesday.

See more from Benzinga

• Click here for options trades from Benzinga

• Amarin's Vascepa Associated With Stroke Reduction

• Pfizer/BioNTech COVID-19 Vaccination Could Protect Pregnant Women, Newborns, Study In Israel Suggests: Reuters

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.